# Vaccine Responses in Cancer

> **NCT06605625** · — · ACTIVE_NOT_RECRUITING · sponsor: **Abramson Cancer Center at Penn Medicine** · enrollment: 250 (estimated)

## Conditions studied

- Viral Vaccines

## Interventions

- **BIOLOGICAL:** Influenza vaccination
- **BIOLOGICAL:** SARS-CoV-2 vaccine
- **BIOLOGICAL:** Zoster Vaccine Recombinant

## Key facts

- **NCT ID:** NCT06605625
- **Lead sponsor:** Abramson Cancer Center at Penn Medicine
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-11-04
- **Primary completion:** 2027-10
- **Final completion:** 2028-10
- **Target enrollment:** 250 (ESTIMATED)
- **Last updated:** 2025-10-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06605625

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06605625, "Vaccine Responses in Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06605625. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*